Crossmark

In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates

Crossref DOI link: https://doi.org/10.1007/s10096-024-04965-x

Published Online: 2024-11-26

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Le Terrier, Christophe https://orcid.org/0000-0002-5455-5576
Raro, Otávio Hallal Ferreira https://orcid.org/0000-0001-7374-0788
Saad, Alaaeldin Mohamed

Nordmann, Patrice https://orcid.org/0000-0002-1343-1622
Poirel, Laurent https://orcid.org/0000-0001-5160-5286
Funding

Funding for this research was provided by:

University of Fribourg
License Information

Text and Data Mining valid from 2024-11-26

Version of Record valid from 2024-11-26
More Information

Article History

Received: 17 July 2024

Accepted: 9 October 2024

First Online: 26 November 2024

Declarations

:

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below